Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.

olutasidenib是一种突变异柠檬酸脱氢酶-1 (IDH1)的小分子抑制剂。在AML患者中，易感性IDH1突变被定义为导致白血病细胞中2羟基戊 ...

禁止与强CYP3A诱导剂合用Sunlenca。 【警告和注意事项】 1.免疫重建综合征据报道，在接受联合抗逆转录病毒(ARV)治疗的患者中，出现了发病时间不定的自身免疫性疾病。 2.Sunlenca的长效特性和潜在相关风险:Sunlenca的残留浓度可能会在患者的体循环中保留长达12个月 ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Vatche and Tamar Manoukian Division of Digestive Diseases, G. Oppenheimer Center for Neurobiology of Stress and Resilience, ...

Table 3. Changes of C 0 /D in patients receiving different CCBs (regardless of genotype). The inhibition of CCBs on CYP3A leads to the decrease of tacrolimus metabolism and the increase of its blood ...

Objective To investigate the efficacy and safety of two different budesonide formulations (effervescent tablet for orodispersible use (BET) and viscous suspension (BVS)) with different daily dosages ...